Journal
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
Volume 13, Issue 7, Pages 1149-1155Publisher
SPRINGER
DOI: 10.1007/s00775-008-0400-9
Keywords
anticancer research; apoptosis; bioorganometallics; p53; ruthenium
Funding
- Department of Science and Technology, India
- Indo Swiss Bilateral Research Initiative (EPFL)
- Austrian Science Fund [J2613-N19]
- [COST D39]
Ask authors/readers for more resources
An investigation of the molecular mechanism of the anticancer activity demonstrated by the ruthenium(II)-arene compound [Ru(eta(6)-p-cymene)Cl-2(pta)] (pta is 1,3,5-triaza-7-phosphaadamantane), termed RAPTA-C, in Ehrlich ascites carcinoma (EAC) bearing mice is described. RAPTA-C exhibits effective cell growth inhibition by triggering G(2)/M phase arrest and apoptosis in cancer cells. Cell cycle arrest is associated with increased levels of p21 and reduced amounts of cyclin E. RAPTA-C treatment also enhances the levels of p53, and its treatment triggers the mitochondrial apoptotic pathway, as shown by the change in Bax to Bcl-2 ratios, resulting in cytochrome c release and caspase-9 activation. c-Jun NH2-terminal kinase (JNK) is a critical mediator in RAPTA-C-induced cell growth inhibition. Activation of JNK by RAPTA-C increases significantly during apoptosis. Overall, these results suggest a critical role for JNK and p53 in RAPTA-C-induced G(2)/M arrest and apoptosis of EAC-bearing mice. Consequently, RAPTA-C treatment results in a significant inhibition in the progression of cancer in an animal model, which emulates the human disease, and does so with remarkably low general toxicity; hence, RAPTA-C has potential for clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available